500257 Stock Overview
Lupin Limited, a pharmaceutical company, develops, produces, markets, and sells a range of branded and generic formulations, biotechnology products, active pharmaceutical ingredients (APIs), and specialty products in India, the United States, Japan, and internationally.
Price History & Performance
|Historical stock prices|
|Current Share Price||₹696.30|
|52 Week High||₹1,267.50|
|52 Week Low||₹678.65|
|1 Month Change||-9.85%|
|3 Month Change||-8.84%|
|1 Year Change||-41.44%|
|3 Year Change||-8.21%|
|5 Year Change||-44.87%|
|Change since IPO||23,305.04%|
Recent News & Updates
|500257||IN Pharmaceuticals||IN Market|
Return vs Industry: 500257 underperformed the Indian Pharmaceuticals industry which returned -11.3% over the past year.
Return vs Market: 500257 underperformed the Indian Market which returned 9.7% over the past year.
|500257 Average Weekly Movement||4.5%|
|Pharmaceuticals Industry Average Movement||6.8%|
|Market Average Movement||7.2%|
|10% most volatile stocks in IN Market||10.0%|
|10% least volatile stocks in IN Market||4.7%|
Stable Share Price: 500257 is less volatile than 75% of Indian stocks over the past 3 months, typically moving +/- 4% a week.
Volatility Over Time: 500257's weekly volatility (4%) has been stable over the past year.
About the Company
Lupin Limited, a pharmaceutical company, develops, produces, markets, and sells a range of branded and generic formulations, biotechnology products, active pharmaceutical ingredients (APIs), and specialty products in India, the United States, Japan, and internationally. It offers formulations for use in the therapeutic areas of cardiovascular, diabetology, asthma, pediatrics, central nervous system, gastrointestinal, anti-infective, nonsteroidal anti-inflammatory drug therapy, respiratory, women’s health, anti-tuberculosis, and cephalosporin, as well as digital therapeutics platform for doctors and patients. The company is also involved in the provision of biosimilar and over-the-counter products; and drug discovery and development programs in the therapeutic areas of oncology, immunology, and metabolic disorders, as well as bio clinical research activities.
Lupin Fundamentals Summary
|500257 fundamental statistics|
Is 500257 overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|500257 income statement (TTM)|
|Cost of Revenue||₹65.49b|
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
May 18, 2022
|Earnings per share (EPS)||-12.09|
|Net Profit Margin||-3.37%|
How did 500257 perform over the long term?See historical performance and comparison
0.9%Current Dividend Yield
Is Lupin undervalued compared to its fair value and its price relative to the market?
Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PB vs Industry
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: 500257 (₹684.65) is trading above our estimate of fair value (₹608.6)
Significantly Below Fair Value: 500257 is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: 500257 is unprofitable, so we can't compare its PE Ratio to the Indian Pharmaceuticals industry average.
PE vs Market: 500257 is unprofitable, so we can't compare its PE Ratio to the Indian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate 500257's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: 500257's PB Ratio (2.6x) is in line with the IN Pharmaceuticals industry average.
How is Lupin forecast to perform in the next 1 to 3 years based on estimates from 29 analysts?
Future Growth Score3/6
Future Growth Score 3/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 500257 is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (6.7%).
Earnings vs Market: 500257 is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: 500257's is expected to become profitable in the next 3 years.
Revenue vs Market: 500257's revenue (9.5% per year) is forecast to grow slower than the Indian market (12% per year).
High Growth Revenue: 500257's revenue (9.5% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 500257's Return on Equity is forecast to be low in 3 years time (12.5%).
How has Lupin performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 500257 is currently unprofitable.
Growing Profit Margin: 500257 is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: 500257 is unprofitable, and losses have increased over the past 5 years at a rate of 42.8% per year.
Accelerating Growth: Unable to compare 500257's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 500257 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (12.4%).
Return on Equity
High ROE: 500257 has a negative Return on Equity (-4.44%), as it is currently unprofitable.
How is Lupin's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: 500257's short term assets (₹133.2B) exceed its short term liabilities (₹92.4B).
Long Term Liabilities: 500257's short term assets (₹133.2B) exceed its long term liabilities (₹14.0B).
Debt to Equity History and Analysis
Debt Level: 500257's net debt to equity ratio (21.2%) is considered satisfactory.
Reducing Debt: 500257's debt to equity ratio has reduced from 54.7% to 48.7% over the past 5 years.
Debt Coverage: 500257's debt is well covered by operating cash flow (49.9%).
Interest Coverage: 500257's interest payments on its debt are well covered by EBIT (20.7x coverage).
What is Lupin current dividend yield, its reliability and sustainability?
Dividend Score 3/6
Future Dividend Coverage
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: 500257's dividend (0.95%) is higher than the bottom 25% of dividend payers in the Indian market (0.37%).
High Dividend: 500257's dividend (0.95%) is low compared to the top 25% of dividend payers in the Indian market (1.64%).
Stability and Growth of Payments
Stable Dividend: 500257's dividend payments have been volatile in the past 10 years.
Growing Dividend: 500257's dividend payments have increased over the past 10 years.
Earnings Payout to Shareholders
Earnings Coverage: 500257 is paying a dividend but the company is unprofitable.
Cash Payout to Shareholders
Cash Flow Coverage: With its low cash payout ratio (13.4%), 500257's dividend payments are thoroughly covered by cash flows.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Vinita Gupta (53 yo)
Ms. Vinita D. Gupta has been the Chief Executive Officer at Lupin Limited since September 1, 2013. Ms. Gupta serves as an Executive Director of Lupin Limited. She has been the Chairman and Chief Executive...
CEO Compensation Analysis
Compensation vs Market: Vinita's total compensation ($USD1.65M) is above average for companies of similar size in the Indian market ($USD610.65K).
Compensation vs Earnings: Vinita's compensation has been consistent with company performance over the past year.
Experienced Management: 500257's management team is considered experienced (2.6 years average tenure).
Experienced Board: 500257's board of directors are considered experienced (3.1 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Lupin Limited's employee growth, exchange listings and data sources
- Name: Lupin Limited
- Ticker: 500257
- Exchange: BSE
- Founded: 1968
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: ₹316.471b
- Shares outstanding: 454.50m
- Website: https://www.lupin.com
Number of Employees
- Lupin Limited
- Kalpataru Inspire
- 3rd Floor
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/05/16 00:00|
|End of Day Share Price||2022/05/16 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.